HONG KONG, Aug 22, 2022 – (ACN Newswire) – Peijia Medical Limited ("Peijia Medical" or the "Company", together with its subsidiaries, the "Group", stock code: 9996), a leading domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets in China, announced its interim results for the six months ended June 30, 2022 (the "Period").

Performance Summary:
— Revenue was RMB118.8 million, representing an increase of 129.8% from the same period of 2021.
— Gross profit (excluding the amortization cost from purchase price allocation) was RMB87.6 million, representing an increase of 133.5% from the same period in 2021, and gross margin (excluding the amortization cost from purchase price allocation) reached 73.7%.

Key Operational Statistics:
— Even under the impact of Covid-19, revenue from theTranscatheter Valve Therapeutic Business and Neurointerventional Business were RMB52.1 million and RMB66.7 million, representing an increase of 455.4% and 57.6% from the same period in 2021, respectively.
— For the Transcatheter Valve Therapeutic Business, both product adoption by new hospitals and the utilization rate of its products in the adopted hospitals exceeded expectation. As of July 31, 2022, within a short period of about one year after TaurusOne(R) and TaurusElite(R) received NMPA approvals, a total of 209 hospitals were entered and the implantation volume repeatly reached monthly highs, accounting for close to 20% of the market share in July. The total implantation volume of the six months ended June 30, 2022 has far exceeded that of the whole year of 2021. The pipeline for the Transcatheter Valve Therapeutic Business was progressing smoothly as scheduled.
— The Group's registration applications of four ischemic products have been approved by the NMPA, and the product portfolio for the ischemic product line has been preliminarily established. The Group can provide a complete set of solutions for hemorrhagic and ischemic stokes. In the first half of 2022, the Group continued expanding its share in the sizable hemorrhagic market, constantly consolidating its leading position in the neurointerventional industry.
— The Group made continuous efforts to optimize the supply chain and optimize the production process to achieve long-term success, and continued to maintain stable production to meet the rapid sales demand growth in the first half of the year.

During the period, the Group recorded a revenue of RMB118.8 million, representing an increase of 129.8% as compared to the same period in 2021. Revenue from the Transcatheter Valve Therapeutic Business and Neurointerventional Business were RMB52.1 million and RMB66.7 million , representing a substantial increase of 455.4% and 57.6% as compared to the same period in 2021, respectively. The increase in revenue was primarily attributable to: (i) commercialization of the second-generation retrievable TAVR product TaurusElite(R); (ii) increased sales revenue from existing neurointerventional products including Tethys(R) Intermediate Catheter and SacSpeed(R) Balloon Dilation Catheter; and (iii) commercialization of multiple new neurointerventional products including Jasper(R) SS Detachable Coil, etc. Gross profit (excluding the amortization cost from purchase price allocation) was RMB87.6 million, representing an increase of 133.5% from the same period in 2021, and gross margin (excluding the amortization cost from purchase price allocation) reached 73.7%.

The impact of Covid-19 in the first half of 2021 further validated the Group's execution capability and operational efficiency. Both business lines exceeded their respective commercialization targets. The Group's pipeline projects progressed smoothly and its production operation and supply chain were well managed. Production fulfillment rate of core products reached around 60% (50% as the baseline) in the first half of the year.

Transcatheter Valve Therapeutic business: The commercialization platform was preliminarily established, setting up a strong foundation for commercialization success. Pipeline products also progressed smoothly, bringing sustainability to the long-term business development.

For the Transcatheter Valve Therapeutic Business, the Group had five registered products and nine product candidates at various development stages. The sales of TaurusOne(R) and TaurusElite(R) products were in good progress. The revenue of the Transcatheter Valve Therapeutic Business increased by 455.4% as compared to the same period in 2021 despite the impact of the pandemic. As of June 30, 2022, the Group had a sales and marketing team of 151 employees dedicated to the sales and marketing of its Transcatheter Valve Therapeutic Business.

Thanks to its outstanding product performance and professional market education and promotion, both product adoption by new hospitals and the utilization rate of our products in the adopted hospitals have accelerated for our Transcatheter Valve Therapeutic Business. As of July 31, 2022, the products of the Group entered 209 hospitals, repeatedly setting new monthly highs in implantation volume. The implantation volume reached close to a market share of 20% in July. For the seven months ended July 31, 2022, the total implantation volume reached close to 650 units, more than twice the implantation volume for the whole year 2021. The second half of the year started with strong momentum. The Group are steadily increasing our market share and striving to outperform other players. The Group have become the top player in certain cities and hospitals, with huge development potential.

The Transcatheter Valve Therapeutic Business has progressed rapidly since its commercial launch, thanks to its cross functional teams comprised of marketing, sales and medical professionals. The all-round support ranges from academic promotion to new technology cooperation, from patient identification to physician training, and from preoperative, intraoperative and postoperative clinical support to meticulous sales service. The rapid development of commercialization has built a solid cash foundation for the long-term development of the Company.

The Group has developed a competitive product pipeline through external acquisitions and internal development, with a wide range of innovative products in development covering major valvular diseases and next-generation technologies. As of August 19, 2022, the Group has four BD projects, which are deployed in the fields of aortic valve replacement for AR, mitral valve replacement, tricuspid valve replacement and mitral valve coaptation augmentation, respectively. In addition to BD projects, its internally developed projects are also widely recognized. Areas of the Group are exploring include improving the durability of prosthetic valves, creating non-implant treatment solution for valve diseases and developing innovative mitral valve repair products.

Among them, three projects are entering into significant clinical trial stages: GeminiOne(R) and MonarQ will enter the registration clinical trial and overseas FIM clinical trial stages, respectively, and HighLife(R) will enter the registration clinical trial stage.

Neurointerventional Business: With the Group's successive launch of four ischemic products, the product portfolio for the ischemic product line has been preliminarily established. The Group are able to provide a complete set of solutions for hemorrhagic and ischemic strokes. With increasing sales from hemorrahagic products and upcoming commercialization of recently approved ischemic products, the revenue composition of the Neurointerventional Business will further diversify.

In the first half of 2022, the registration applications of four products have been approved by the NMPA, namely, Syphonet(R) Stent Retriever, Tethys AS(R) Aspiration Catheter, Fastunnel(R) Delivery Balloon Dilation Catheter and Fluxcap(R) Balloon Guide Catheter. The product portfolio for the ischemic product line has been preliminarily established, with all major devices readily in place, forming a complete solution for patients with AIS and ICAD.

As of now, for the Neurointerventional Business, the Group had fourteen registered products and seven product candidates at various development stages. The Group have a comprehensive portfolio of registered and pipeline products that target both hemorrhagic and ischemic stroke markets, providing one-stop solution for both hemorrhagic and ischemic strokes with a complete line of core products. This will not only build its resilience in times of change and uncertainty, but also enhance the attractiveness and synergy of its product portfolio among physicians and distributors.

Thanks to the superior product performance, strong marketing capability as well as stable and in-depth distributor network, revenue from the Neurointerventional Business increased by 57.6% during the period, as compared to the same period in 2021. The revenue generated from the sales of hemorrhagic, ischemic and vascular access products accounted for 44.2%, 25.0% and 30.6% of the total revenue of the Neurointerventional Business, respectively. With increasing sales from hemorrahagic products and upcoming commercialization of recently approved ischemic products, the revenue composition of its Neurointerventional Business will further diversify.

As of June 30, 2022, the Group had 177 distributors, covering more than 1,800 hospitals in 31 provinces nationwide. The Group will continue to build on its sales team and distributor coverage in response to its expanding ischemic product portfolio. As of June 30, 2022, the Group had a sales and marketing team of 74 employees focusing on the sales and marketing of neurointerventional products.

As of June 30, 2022, the Group had a robust intellectual property portfolio, consisting of a total of 89 granted and valid patents and 100 patents under application. Specifically, there are 53 granted and valid patents and 74 patents under application for our Transcatheter Valve Therapeutic Business, and 36 granted and valid patents and 26 patents under application for its Neurointerventional Business.

Dr. Yi Zhang, Executive Director, Chairman of the Board and Chief Executive Officer of Peijia Medical Limited, said "As one of the world-class medical device leader rooted in China, Peijia Medical will strive to strengthen the Group's leading position in the industry by implementing a series of future strategies and plans. Looking forward, the company will continue to develop and commercialize interventional solutions for structural cardiac and neurovascular diseases in China and globally in line with its corporate vision. Meanwhile, the Group will continue to actively promote the clinical trials of pre-clinical products in development, and try our best to bring positive and effective treatment options to patients as soon as possible."


Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

HONG KONG, Aug 22, 2022 – (ACN Newswire) – IVD Medical Holding Limited ("IVD Medical" or the "Group"), a leading distributor of In Vitro Diagnostic ("IVD(1)") products in the PRC, has announced its interim results for the six months ended 30 June 2022 ("Period").

During the Period, although hospitals were closed and other quarantine and social distancing measures were put in place in mainland China due to the COVID-19 pandemic, which resulted in a temporary decrease in end customers' demand for IVD product. With the help of its competitive and diverse product portfolio, extensive distribution network and growing maintenance services business, the Group still recorded revenue of RMB1,176,557,000 (six months ended 30 June 2021: RMB1,186,791,000), a similar level to that in the same period last year. Gross profit increased by 11% year-on-year to RMB266,423,000 and gross profit margin was up 2.4 percentage points year-on-year to 22.6%. The increases were mainly attributable to the decrease in purchase price of IVD analysers and the increase in maintenance services revenue with relatively stable maintenance cost. Driven by rising profit margin, the Group's adjusted profit for the period amounted to RMB96,773,000, 6.7% more year-on-year. The Board resolved to declare the payment of an interim dividend of HK2.729 cents per share for the six months ended 30 June 2022.

Mr. Ho Kuk Sing, Chairman of IVD Medical, said, "In 2022, although the business environment of the medical industry has been tough under the pandemic, we have worked hard to overcome challenges and optimize our business operations. For distribution business, we signed a five-year exclusive distribution agreement with Sysmex in April this year. We have expanded our distribution network and hospital coverage to consolidate our position in the industry. Furthermore, our maintenance services business has been developing steadily with the notable growth in revenue, gross profit and gross profit margin. Looking ahead, we are prepared to capture potential growth opportunities in the industry and committed to bring better and long-term returns to shareholders."

Business Review
The Group is a leading distributor of IVD products in the People's Republic of China ("PRC"). It has also engaged in research, development, manufacturing and sales of its self-branded IVD products.

Distribution Business
The distribution of IVD products forms the cornerstone of the Group's business. It primarily involves the trading of IVD analysers, reagents and other consumables to customers such as distributors, hospitals and healthcare institutions and logistics providers. During the Period, revenue from this segment was RMB1,097,468,000, with gross profit up 3.1% to RMB216,907,000.

Through years of operation, the Group has established an expansive distribution network across 29 provinces, municipalities and autonomous regions in the PRC with an extensive hospital coverage. As of 30 June 2022, the Group has 204 direct customers, including hospitals and healthcare institutions, and 908 distributors in its established distribution network.

The Group distributes IVD products through its wholly-owned subsidiary Vastec Medical Limited ("Vastec"). Vastec has been the sole nationwide distributor of Sysmex haemostasis products with exclusive distribution rights in the PRC since 1997, and also procures a diversified portfolio of IVD products from other leading international brands for distribution in the PRC. On 1 April 2022, Vastec signed a five-year distribution agreement of Sysmex haemostasis products with exclusive distribution rights which is valid till 31 March 2027. The agreement has helped to strengthen the long-term and quality cooperation between Vastec and Sysmex.

Moreover, the Group has provided four Thrombotic Markers(2) products manufactured by Sysmex to the market. These products adopt highly sensitive chemiluminescence technology, which may facilitate early diagnosis of thrombosis and fibrinolysis.

The Group also provides solution services to clinical laboratories of hospitals, as such, it has enabled the Group to establish and maintain direct relationships with local medical practitioners so as to keep the Group close to the frontline of the medical practice and the demand of IVD products. In the first half of 2022, the Group provided solution services to eight Class III hospitals in the PRC.

Maintenance Services
The Group provides maintenance services to end customers of Sysmex' haemostasis analysers. In 2017, Vastec entered into a maintenance services agreement with Sysmex to provide maintenance services to haemostasis analysers procured by its end customers. The maintenance services provided by Vastec generally include maintenance and repair services, installation services and end customer trainings. And, it primarily provides its maintenance services to hospitals and healthcare institutions. During the Reporting Period, the maintenance services business has been sustainably and steadily developing, with revenue amounted to RMB77,286,000, up by 27.8% against the same period last year. Gross profit of this segment increased by 70.2% to RMB48,388,000 and gross profit margin was up 15.6 percentage points to 62.6% for the period.

Self-Branded Products Business
The Group has also engaged in the research and development, manufacturing and sales of IVD analysers and reagents under its own brand. The Group's self-branded IVD reagents were manufactured by Suzhou DiagVita Biotechnology Co., Ltd. and Bazoe Medical Co., Ltd., and the Group's IVD analysers were produced by its equipment manufacturers, IVD Medical Equipment (Shanghai) Ltd. and Langmai Biotechnology (Shandong) Co., Ltd. In addition, the Group distributes self-developed IVD products under its own brand which includes IVD analysers and reagents primarily under the IVD testing category of Point-of-care testing ("POCT"), mass spectrometry and microbiology.

Outlook
In the future, the Group will continue to consolidate its leading position in the IVD industry in the PRC. To realise this goal, the Group aims to continuously expand its product portfolio by diversifying product categories, increasing brand coverage, and further expanding the breadth of its distribution network and hospital coverage. In this way, the Group will be able to capitalise on the high growth potential in the IVD market.

Furthermore, the Group will continue to develop its distribution business by enhancing its capacity in providing solution services. By being the general supplier of the clinical laboratory department in such hospitals, the Group participates in the design of laboratory layout, provides centralised procurement of IVD products, conducts real-time inventory monitoring and provides other after-sale services to clinical laboratories. It also plans to hire more sales personnel to promote and market its solution services and to stock sufficient IVD products of various brands to strengthen its advantages in centralized procurement. To enhance brand awareness, it will continuously participate in national and local IVD symposiums, as well as academic conferences.

In addition, the Group believes that strong research and development ("R&D") capabilities are critical to securing its future development and sustainable growth. It will therefore invest more resources to further improve its R&D capabilities by acquiring equipment, instruments and hiring experts in the relevant fields. The Group will also engage in research projects to further develop self-branded IVD products that holding promising market potential. The Group is keen to further strengthen product quality management and optimize the performance and applicability of self-developed products to improve market competitiveness.

Mr. Leung King Sun, Chief Operation Officer of the Group, said, "Given the growing medical expenses per capita and government support to the industry pursuing technological development, the Group remains optimistic about the development prospects of the medical market in the PRC, particularly the medical equipment market. Priding competitiveness, a diverse product portfolio, an expansive distribution network and extensive hospital coverage, we are confident of seizing every potential opportunity. Meanwhile, we will continue to strengthen solution services for hospitals and enhance R&D capabilities for our own brands, and ultimately consolidate our leading position in the industry."

About IVD Medical Holding Limited
IVD Medical Holding Limited ("IVD Medical" or the "Group") is a leading distributor of IVD products in the PRC. Its key subsidiaries include Vastec Medical Limited, Dacheng Medical Equipments (Shanghai) Co., Ltd., IVD China Limited, Suzhou DiagVita Biotechnology Co., Ltd., Langmai Biotechnology (Shandong) Co., Ltd and Bazoe Medical Co., Ltd. The Group's distribution network covers 29 provinces, municipalities and autonomous regions across the PRC. It is the sole national distributor of Sysmex' haemostasis products in the PRC and provides maintenance services to its end customers. It also engages in the R&D, manufacturing and sales of self-branded IVD analysers and reagents and provides solution services to clinical laboratories of hospitals for centralised procurement.

Notes:
(1) IVD, "In Vitro Diagnostic", which encompasses tests done on samples such as blood or tissue taken from the human body
(2) 4 Thrombotic Markers refer to: 1)TAT: Thrombin-antithrombin complex, 2)PIC: Plasmin – a2-plasmin inhibitor complex, 3)TM: Thrombomodulin, 4)t-PAI-C: Tissue plasminogen activator/plasminogen activator inhibitor-1 complex.

Media Enquiries:
Strategic Financial Relations Limited
Heidi So Tel: (852) 2114 4320 Email: heidi.so@sprg.com.hk
Yan Li Tel: (852) 2864 4826 Email: yan.li@sprg.com.hk
Cherry Chen Tel: (852) 2114 4309 Email: cherry.chen@sprg.com.hk
Fax: (852) 2527 1196


Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

HANGZHOU, Aug 19, 2022 – (ACN Newswire) – New Horizon Health (6606.HK), China's leading biotechnology company for early cancer screening, announced its half-year results for the year ended June 30, 2022 today.

Based on the financial information before the audit as of June 30, 2022, New Horizon Health achieved total revenue of RMB226 million in the first half of 2022, an increase of 414% over the same period in 2021; achieved a gross profit of RMB185 million, an increase of 650% over the same period in 2021; gross profit margin climbed to 82.0% from 56.2% in the first half of 2021. The Company's adjusted net loss for the half-year was RMB106 million and the adjusted net loss rate(1) narrowed significantly from 221% to 47%; the ratio of expenses to sales(1) dropped significantly from 161% to 86%, and the ratio of management expense to sales(1) dropped significantly from 80% to 23%. The Company's total cash, including time deposits, cash, and cash equivalents, amounted to RMB1.65 billion.

The Company announced its cervical cancer screening product, CerviClear(TM), which had been launched in a large-scale prospective multi-center registered clinical trial in June 2022. CerviClear(TM) is the world's first HPV cervical cancer screening product that provides painless and non-invasive urine self-sampling at home, covering a comprehensive range of 14 high-risk HPV viruses. The clinical trial for LiverClear(TM) is progressing well and is expected to be launched in the fourth quarter of 2022 or the first quarter of 2023. As of June 30, 2022, the Company's R&D expenses(1) were RMB39.4 million, an increase of 111% over the same period in 2021.

"The results of the interim report were not easy to get. New Horizon Health's team is faithful to its promise that it is able to do what it says and do what it does. The Company's revenue in the first half of the year has exceeded last year's full-year revenue. The performance growth is mainly attributed to the increase in revenue and gross profit of ColoClear and Pupu Tube, as well as the listing of UU Tube. The underlying logic of the high growth and high gross profit of the three products is that more and more people with high risk are accelerating the change of concept, attaching importance to the risk prevention and control of high incidence cancer in personal and family health management, recognizing the important value of cancer early screening product compliance and willing to pay for it", the Chairman and CEO of New Horizon Health, YeQing ZHU, said, "Cancer early screening products are both serious medical and consumer products, and the huge market opportunity is backed by the high barrier of research and development and compliance as well as the high investment in market education. The necessary condition for the approval of cancer early screening products under New Horizon Health is solid prospective large-scale multi-center registration clinical validation, which is the strong barrier of our diversified business strategy and the foundation of user trust."

Normalization of COVID-19 epidemic accelerates the market education process for early screening at home: ColoClear and Pupu Tube continue to see 3-digit revenue growth

ColoClear achieved revenue of RMB73.6 million in the first half of 2022, representing an increase of 419% over the same period in 2021. The shipment volume in the first half of the year was approximately 294,600 kits, representing an increase of 143% over the same period in 2021. The increase in revenue of ColoClear was mainly due to the increase in volume sold and recognized as revenue and the increase in average recognition unit price.

China's first at-home self-testing FIT test product, Pupu Tube, achieved revenue of RMB68.5 million in the first half of 2022, an increase of 132% over the same period in 2021; and achieved shipment of 2,929,700 units, an increase of 54% over the same period in 2021. The increase in revenue recognized by Pupu Tube was mainly due to the increase in sales volume and the increase in the average unit price (including the increase in the unit price of direct-to-consumer pipeline and the increase in the unit price of health check centers).

Other than New Horizon Health, no domestic player has yet announced the launch of a large-scale prospective multi-center registration clinical trial for colorectal cancer screening. ColoClear is the only product approved by the National Medical Products Administration of China for screening cancer. Pupu Tube is the only approved product for at-home self-testing of FIT in China. In February 2022, ColoClear's multi-target stool FIT-DNA technology was recommended by the latest version of the Cancer Foundation of China's "China Integrated Cancer Treatment Guidelines", making it the only molecular early screening technology in China to be included in all national guidelines for colorectal cancer prevention and treatment.

In the first half of 2022, the policy of early screening of cancer at home was intensively favorable. The "14th Five-Year Medical Equipment Industry Development Plan ", the "14th Five-Year National Health Plan " and the "14th Five-Year Bio-economic Development Plan " all focus on "early screening and health management of key diseases" such as cancer and in vitro diagnosis in home scenes. The normalization of the detection of COVID-19 epidemic has accelerated the public's awareness of home screening and healthy "symptom-free" people.

The only consumer self-test for H. pylori testing: $83.5 million in half-year sales revenue for UU Tube
As of June 30, 2022, the sales revenue of UU Tube since its listing on January 18, 2022, was RMB83.5 million.

On December 31, 2021, UU Tube was approved for registration as a Class III medical device by the National Medical Products Administration of China and is the only product in China that is suitable for "consumer self-testing" for H. pylori detection, for which we have the exclusive patented design of the "pregnancy test stick" which is an integrated design for sampling and testing.

Data show that more than half of the users of UU Tube are women, nearly 50% are aged 31-40, and people aged 24-30 and 40-50 are also the main users. Jiangsu, Guangdong and Zhejiang have ranked the top three provinces in terms of the number of UU Tube users, and household users are more concerned about the detection and prevention of H. pylori.

The prevention and control of H. pylori is a major focus of the science of gastric cancer prevention and has been receiving widespread attention from the media and the public. Data show that in the first half of 2022, the epidemic prevention and control led to a significant decline in the measurement of H. pylori breath tests in hospitals and health checkups, while the number of online and offline gastroenterology consultations continued to rise during the same period, effectively boosting consumer demand for home testing of H. pylori and strongly supporting the rapid promotion of H. pylori.

Diversification of 2C quality pipes in tandem: ColoClear, Pupu Tube and UU Tube have excellent profitability performance

In the first half of 2022, all the three marketed products demonstrated excellent profitability, with the gross margins of ColoClear and Pupu Tube continuing to increase significantly compared to the same period in 2021. As of June 30, 2022, the gross margin of ColoClear reached 75.7%, the gross margin of Pupu Tube reached 80.0% and the gross margin of UU Tube reached 90.0%. Compared to the same period in 2021, the gross margins of ColoClear and Pupu Tube were 56.6% and 59.0%, respectively.

The Company's sales volume of the core pipeline increased steadily in the first half of 2022, and the new pipeline continued to make efforts to take advantage of the favorable macro and micro home inspection policies in the first half of the year with "Resilient" marketing and firmly implementation. The high gross margin of the three products benefited from the Company's continuous and in-depth diversified business strategy, which optimized the pipeline mix for product sales, increased the revenue of single test for direct-to-consumer pipelines and brought about scale production through operational leverage benefits, which further reduced the operating cost of a single test.

In the first half of the year, the Company has been making progress online and offline, both inside and outside the hospital. As of June 30, 2022, the Company has completed access and sales to over 800 hospitals in the first half of the year. During the "618" period, New Horizon Health continued to be the champion in sales of JD in three categories: medical devices, consumer medical and genetic testing. UU Tube won the top selling category of Tmall test paper. The Company's total sales in JD and Tmall exceeded RMB40 million, representing a 400% increase in total sales compared to the same period in 2021, and a 300% increase in sales of ColoClear YoY.

Based on the mainland market, start international marketing: ColoClear debuted in Hong Kong and will advance to Southeast Asia in phases

2022 is a milestone year for the internationalization of New Horizon Health. On May 23rd, the Company and Prenetics (Nasdaq: PRE) made a joint announcement that the two parties have launched in-depth cooperation to fully integrate the quality resources in market and pipeline development and product and service operation, and jointly promote the market coverage of ColoClear in Hong Kong, Macau and Taiwan, China, and explore the market opportunities in countries or regions in Southeast Asian at the same time. On June 8, ColoClear by Circle was officially launched in Hong Kong with an official price of HK$3,000. During the cooperation period, ColoClear is the colorectal cancer early screening product that Prenetics has exclusively partnered with.

At the same time as ColoClear's debut in the Hong Kong market, New Horizon Health announced the establishment of the Company's first international R&D center in the Hong Kong Science and Technology Parks to attract global talent and focus on multi-omics cancer screening technology innovation and product development, including NGS, and to drive overseas commercialization and synchronized global clinical trials.

About New Horizon Health

Founded in 2015, New Horizon Health is a pioneer and leader in China's cancer screening market, focusing on early home screening of high-incidence cancers, aiming to promote innovation in cancer screening technology and accelerate the popularity of cancer screening technology in China. On February 18, 2021, New Horizon Health was successfully listed on the SEHK with stock code 6606.HK, which became "the first listed Chinese cancer early screening company".

New Horizon Health has three marketed products. ColoClear, Pupu Tube and UU Tube have all been approved by the National Medical Products Administration of China and are officially commercialized. ColoClear is the only cancer screening product approved by the National Medical Products Administration of China for people aged 40-74 who are at high risk of colorectal cancer. UU Tube is the only consumer self-test product for Helicobacter pylori approved by the National Medical Products Administration of China. Pupu Tube is the first FIT at-home self-test device approved in China. In addition, the Company has three pipelines of products in development for liver cancer (LiverClear), cervical cancer (CerviClear ) and nasopharyngeal cancer screening. The Company has global rights to all of its marketed and pipeline products. New Horizon Health works extensively with hundreds of hospitals, health check-ups, insurance companies, pharmacies and online channels. The Company has a class 100,000 clean production workshop that meets ISO13485 and ISO9001 international certification standards. The third parties medical testing laboratories in Beijing, Hangzhou and Guangzhou have been certified by international quality standards and the local health care commission and issued licenses to practice, with an annual testing capacity of 2 million people.

(1) Excluding equity incentive-related expenses

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com

HONG KONG, Aug 16, 2022 – (ACN Newswire) – Essex Bio-Technology Ltd ("EssexBio" or the "Group", Stock Code: 1061.HK) is pleased and honoured to announce that it is included in "Forbes Asia's 200 Best Under A Billion 2022" – for the Group's outstanding long-term sustainable development across a variety of metrics.

Only 200 companies were selected out of 20,000 publicly traded companies (with annual sales of between $10 million and $1 billion) in the Asia-Pacific region. The 200 companies were carefully picked based on Forbes' List Methodology ^ of quantitative criteria and qualitative screens.

EssexBio would like to extend its gratitude to all stakeholders for their contributions. For sustainable long-term growth and enhancing shareholder value, EssexBio will continue to strive for excellence by embracing innovation to develop first-in-class and best-in-class products – providing solutions for Tomorrow's healthcare problems, Today.

About Essex (1061.HK)
Essex Bio-Technology Limited is a biopharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic b-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998. Additionally, it has a portfolio of commercialised products of preservative-free unit-dose eye drops and Shilishun (Iodized Lecithin Capsules) etc. The products of the Company are principally prescribed for the treatment of wound healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 10,500 hospitals and managed directly by its 43 regional sales offices in China. Leveraging on its in-house R&D platform in growth factors and antibodies, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields and indications.

^Forbes' List Methodology (Source: forbes.com)
This list is meant to identify companies with long-term sustainable performance across a variety of metrics. From a universe of 20,000 publicly traded companies in the Asia-Pacific region with annual sales above $10 million and below $1 billion, these 200 companies were selected. The companies on this list, which is unranked, were selected based on a composite score that incorporated their overall track record in measures such as debt, sales and earnings-per-share growth over both the most recent fiscal one- and three-year periods, and the strongest one- and five-year average returns on equity. Aside from quantitative criteria, qualitative screens were used as well, such as excluding companies with serious governance issues, questionable accounting, environmental concerns, management issues, or legal troubles. State-controlled and subsidiaries of larger companies were also excluded. The criteria also ensured a geographic diversity of companies from across the region. The list uses full-year annual results, based on the latest publicly available figures as of July 11, 2022.

Copyright 2022 ACN Newswire. All rights reserved. http://www.acnnewswire.com